A previous study has indicated that EGFR-mutant NSCLC is characterized by a high infiltration of CD4 + effector regulatory T cells, which can be reduced by the administration of EGFR inhibitors in in vivo experiments. This evidence concerns the gene EGFR and non-small cell lung carcinoma.